The introduction of antiretroviral therapy (ART) has meant a drastic change in HIV-infected patients’ prognoses. Since its introduction, survival rates have continued to increase, even in developing countries.1–3 Moreover, high activity ART (HAART) has reduced the incidence of AIDS-related diseases and hospitalizations.4 Among patients with good immunovirological conditions, HIV infection has become a chronic disease. However, immune system restoration is incomplete in these patients and there remains an inflammatory condition which, in the long-term, is related to pathologies such as cancer and cardiovascular diseases. This chronic inflammatory profile, along with longer survival and possible toxicity accumulation from HAART, will mean that HIV-infected elderly patients have a high burden of “special” comorbidities known as HIV-associated non-AIDS (HANA)5 which will cause their hospital admissions.

HAART has also led to a significant change in both the profile and prognosis of HIV patients admitted to intensive care units (ICU). At the start of the pandemic in the early 1980s, 70% of admissions were due to respiratory failure secondary to pneumonia caused by Pneumocystis jiroveci (formerly known as Pneumocystis carinii, hence its acronym: PCP). However, since HAART was introduced, the rate of patients admitted to the ICU with AIDS-related diseases has dropped, as has the associated mortality. In Europe and North America, short-term mortality of approximately 20–30% (survival higher than 90% in the ICU) has been reported, as has survival of 85% at one year and higher than 70% at two years.6–23 Although with higher mortality than in Europe and North America, decreased mortality has also been observed in countries such as Brazil, Mexico, China, Taiwan and Australia, where intra-ICU and hospital mortality varies from 37% to 68% and 48% to 68%, respectively.24–30 In Spain, higher mortality has been published compared with other developed countries (36.5%, 67.9% and 80.9% at 30, 60 and 90 days, respectively)31 without evidence of a decrease over the HAART period.32

However, despite the decreased mortality in HIV patients admitted to the ICU, this is still greater than in non-HIV patients.20,23,31 Results from analyses of prognostic factors in this patient group have varied. Some study authors have concluded that the patient's immunovirological condition determines the prognosis,26,28 while others have stated that prognosis depends on disease severity that led to ICU admission19,21,22,25,27,33 and comorbidities.21,22,31

Our study aim was thus to describe the epidemiology of critical pathology in HIV patients in a cohort of patients admitted to ICU, during the current HAART period and to identify factors that predict mortality during hospital admission.

A total of 297 admissions were recorded; among these, 14 patients were admitted twice, so only the initial 283 episodes were included for final analyses. The patient sample characteristics are shown in Table 1.

A total of 71 patients (25.1%) died during their admission to the ICU, while another 22 died before hospital discharge, translating to a total hospital mortality of 32.9% (95% CI=21.2–38.5%). Among these 14 patients who were admitted twice, 11 (78.6%) died during hospital stay.

Median ICU and hospital LOS were 52,13 and 189,37 days, respectively.

In this sample, 68.9% fulfilled the AIDS criteria following CDC 1993 criteria.34 Following new definitions35 11.7% patients were in stage 0, 12.0% in stage 1, 14.1% in stage 2, 59% in stage 3 and 3.2 in stage unknown. Among patients with a known HIV infection, 62% were under HAART at the time of admission (54.8% of the total sample). Their CD4 count was 167.0 (53.5, 414.0)cells/mm3 and VL was log 2.9 (0.0, 5.3), with 22.6% having an undetectable VL. Patients who survived their hospital admission, compared with those who died, received ART more frequently (58.9 compared with 46.2%, p<0.01) and had a better immunovirological profile: higher CD4 count (204.0 (74.0, 493.5)cell/mL compared with 80.0 (29.0, 236.5), p<0.01), and lower VL (2.6 (0.0, 5.0) log compared with 4.5 (1.1, 5.5), p=0.02).

The most common comorbidity in this sample was liver disease (present in 65.4%), with 60.1% co-infected with HCV (Appendix A. Supplementary data, Table e1). Their CCI (median, IQR) was 62,7 points. Both moderate–severe liver disease and CCI were statistically higher in patients who died in the hospital. A total of 24.7% of all patients were reported as cachectic upon physical examination, with median albumin 2.6 (2.1, 3.3)g/dL and a statistically high proportion of cachectic patients and lower albumin figures among those who did not survive.

The most common cause for admission was severe sepsis/septic shock (SS/SS) (49.5%), followed by admissions with a cardiologic origin (19.4%) (Appendix A. Supplementary data, Table e2). 61.3% of patients who died had been admitted due to SS/SS.

APACHE II scores upon admission and SOFA scores during the first 24h were 18.05±9.05 and 6,3,9 respectively. A total of 60.8% of patients required respiratory support with invasive mechanical ventilation (MV) (length of MV: 7 days [2, 13.75]); 40.3% received vasoactive drugs (VADs) (length of VADs: 2 [1, 4] days), and 11% required RTTs (5 [2, 11] days). Patients who died in the hospital presented significantly higher severity scores at admission and required more frequent respiratory, haemodynamic and renal support.

Comparison between the three periods is shown in Table 2. During the study period, the figures for hospital mortality did not vary significantly, being 30.3% among patients admitted in 2000–2004, 31.8% in 2005–2009 and 36.4% in 2010–2014 (annual percentage of change=1.6; 95% CI −2.3 to 5.8, p=0.39).

In Table 3 we present differences between patients who were receiving HAART at the moment they were admitted to ICU with whose were not and, on the other hand, between those patients who received HAART during their ICU stay and those who not.

We found HAART-related complications in less than 10% of patients who receive treatment during ICU stay (Appendix A. Supplementary data, Table e3), more frequently in patients without previous ART (26.9 vs 3.5%, p<0.01).

Factors significantly associated with hospital mortality on univariate analysis were included in the final regression model, and we found that only admission from a site other than the ED ((OR 3.64, 95% CI 1.30–10.20, p=0.01), the existence of moderate–severe liver disease (OR 5.65, 95% CI 1.11–28.87, p=0.04), APACHE II (OR 1.14, 95% CI 1.04–1.26, p<0.01) and SOFA at 72h (OR 1.19, 95% CI 1.02–1.40, p=0.03) maintained a statistically significant relationship with hospital mortality (Table 4).

Our study describes the HIV-infected patient population that required ICU admission over a relatively long period (15 years), and during the current period of ART. Consistent with most publications to date, we found that critical patients infected with HIV are young and predominantly male. In our study, we could not prove a relation between immunovirological or nutritional status, reason for admission or need for organ support and hospital mortality. Variables related with higher hospital mortality in our patients were severity scores (APACHE II at admission and SOFA at 72h), moderate–severe liver disease and admission form hospital ward. Our data provide important insight regarding the complex management of hospitalised HIV-infected patients. Sepsis remains the leading cause of ICU admission in the current HAART era. Mortality, although higher, increasingly approximates that of non-HIV patients.

Our population has a long-standing history of clinical course of infection (median nine years from diagnosis, increasing up to 12 in last five years of our study) and very few patients were diagnosed during their current admission (less than 12%). These data are similar to those recently published describing industrialized countries.22,28,33 However, in the studies by Chiang et al. and Xiao et al., the clinical course of the disease was much shorter (less than a year), with a high percentage of diagnoses during admission (approximately 50%).26,29

At present, it is widely currently recommended that HAART be administered to all HIV-infected patients, regardless of immunovirological profile or symptoms. However, despite that proportion of patients receiving HAART is increasing, only 54.8% of our patients were under HAART at admission. These data are comparable to those reported by other countries from our region,18,28,33 and the level in Spain is higher than in the studies published from countries such as Australia, Brazil, Taiwan and China (in which less than 40% of patients received ART),22,26,27,29 but far from the 71% reported in the USA by Akgün et al.20 This variability in the percentage of patients who receive ART is reflected in their CD4 T-lymphocyte counts at admission. Among our patients, the median was 167cells/mm3 (53.5, 414.0); in studies with a lower percentage of patients receiving ART, the CD4 count is lower, even falling below 50cells/mm3.26,29

As in other recent studies, despite our patients’ relatively good immunovirological conditions, almost half were admitted to the ICU because of infection.22,23

Consistent with previous reports,22,31 13.1% of our patients presented with chronic liver disease with cirrhosis or PHT. HCV co-infection is very common in HIV patients and varies between 15% and 60%19,31; in our sample, 60.1% of patients presented with HCV co-infection.

ICU and hospital mortality (25.1% and 32.9%, respectively) observed in our study was comparable to the figures reported for other industrialized countries6–23 and lower than those reported for developing countries (higher than 40%)24–30 and in other Spanish studies.31,32 These observed mortality differences are probably of multifactorial origin and impact both factors such as extra-hospital treatment for these patients (follow-up in consultations, HAART, management of comorbidities, etc.) and the care received during hospital admission (ICU admission criteria, organ support provided, etc.).

We did not find a significant relationship between immunovirological condition, receiving ART, or years of evolution of infection and hospital mortality. These data coincide with those reported in most,8,10,15,16,18,19,22,26,27,29,33,36,37 although not all,11,13,17,22,24,26,28,38 studies published to date. Probably the difficulty in detecting an independent relationship between mortality and inmunovorological status lies in the fact that patients who receive HAART have not only a higher CD4 count and a lower VL but also a better nutritional status and a different reason for ICU admission. Nevertheless, a larger sample size could, perhaps, give us a statistically significant relation of CD count with mortality.

Furthermore, some studies have related the use of HAART during the ICU stay to lower intra-ICU mortality without impacting long-term survival.19,25,27,33 A meta-analysis including 12 retrospectives studies, published in 2017, showed a significant benefit on short-term mortality when HAART is received during ICU stay, but long-term benefit remains unclear.39 Herein, despite we found a lower hospital mortality in patients having HAART both previously and during ICU stay, we could not prove a significant relationship between receiving HAART and hospital mortality. Although is possible that inclusion of a higher number of patients would change this, there were important differences between these groups. On the one hand, patients under HAART at admission had a better immunovirological and nutritional status, less ICU admissions caused by sepsis and lower severity scores at admission. On the other hand, severity scores were higher in patients who did not receive HAART during ICU stay and patients who receive HAART on ICU were more frequently under treatment at admission (with a consequent better immunovirological status). It's remarkable that only 54% patients with chronic HAART treatment receive it during ICU stay. HAART administration in ICU is complicated due to limited availability of parenteral ART and unknown pharmacokinetics of enteral administration through nasogastric tubes in patients receiving mechanical ventilation or in shock, risk of potential drugs interactions and risk of provoking immune reconstitution inflammatory syndrome. The delay in the start of HAART in ICU was 1 (0, 5) day, but was higher in patients with invasive mechanical ventilation [4.5 (1, 7) compared with 0 (0, 1) days in no-ventilated patients, p<0.01] or in shock [5 (1, 8.5) vs 1 (0, 3) days].

Just as in other studies,21,27–30 delayed ICU admission from patient hospital arrival (here defined as admission not from E.D.) significantly increased the risk of death during the hospital stay. Factors such as initially inadequate treatment, poor response to that treatment, or onset of complications during the hospital stay may justify the relationship between delayed admission and higher mortality.

In the current era, in which HIV infection is controllable with ART, comorbidities play an increasingly important role in patient prognosis. Patients with a history of moderate–severe liver disease have a higher risk of hospital death in our study and those by Barbier et al., Turvey et al. and Medrano et al.21,22,31 We did not find relation between other comorbidities and mortality.

It has been proposed that, nowadays, the mortality among ICU-admitted HIV patients is related to the severity of their acute event. Higher severity scores among critical patients at admission, such as APACHE II or SAPS II, have been related to higher mortality.19,21,22,25,27,28,33 This was observed in our study, in which risk of death increases close to 20% for each point on SOFA score evaluated at 72h and more than 10% for each point on the APACHE II score. However, we did not find a significant relationship between the SOFA at ICU admission and mortality, which probably reflects that in order to establish the prognosis it is more important to assess the response to treatment than the initial organ dysfunction. Regarding the need for organ support, evidence is contradictory, with discrepancies as to the relationship between hospital mortality and the need for respiratory support with invasive MV,19,21,22,25,27,29 for VADs19,21,22 and for RRTs.21,22,29 In our study, the need for support did not predict hospital mortality once we adjusted for severity, reason for admission and comorbidities.

While some studies have reported poorer prognosis in patients admitted to the ICU because of infection,25,30 we did not detect any relationship between the reason for ICU admission and prognosis. These differences may be based on patients’ immunovirological profiles at admission, because more immunosuppression increases their risk of admission due to OIs, which then lead to a worse prognosis.

Finally, we found important differences between the three periods (2000–2004, 2005–2009 and 2010–2014). First, patients were older and with more years living with HIV in most recent periods. Second: proportion of patients receiving HAART also increases significantly, with a consequent decrease in HIV viral load. Third, severity scores were higher in most recent periods. We did not find changes in mortality over time (Table 2).

Our study is not without limitations. First, it was observational and retrospective. Second, although two sites took part, both are in the same geographic setting, limiting the extent to which we can generalize the results. Third, data on ART administration were obtained from clinical records; no drug level tests were performed either at admission or during the ICU stay. Thus, it is possible that patients noncompliant with treatment were not detected. Fourth, only physical examination and albumin levels at admission were used to evaluate nutritional status; we do not have other useful data such as body mass index. Fifth, a recruitment bias cannot be ruled out, because neither of the two units taking part have defined ICU admission criteria for HIV patients; we identified patients retrospectively using the hospital records system. Finally, our study includes patients over 15 years, which may reduce its external validity.

Delayed ICU admission, comorbidities and severity of critical illness, determine the prognosis of HIV-infected patients admitted to the ICU. We did not detect any impact of immunovirological or nutritional condition, reason for admission, or need for organ support during admission. Based on these data, HIV patients should receive the same level of care as non-HIV-infected patients, regardless of their immunological or nutritional condition. We can not prove a relationship between receiving HAART and prognosis, but we have shown significant differences between patients who receive and do not receive treatment before ICU admission (better nutritional and inmunovirologic status, and less severity, sepsis-related admissions and need for mechanical ventilation in HAART patients) and during their ICU stay (better immunological status, less HCV-infected patients and less severity and more cardiac-related diagnosis in patients who received HAART).

Pablo Vidal-Cortés has participated in the conception and design of the study and the acquisition, analysis and interpretation of the data and has made the draft of the article.

Luis Antonio Álvarez-Rocha has participated in the conception and design of the study, and in the critical review of intellectual content. He has approved the version that is presented.

Paula Fernández-Ugidos has participated in the acquisition of data and has approved the version presented.

Marcos Antonio Pérez-Veloso has participated in the acquisition of data and has approved the version presented.

Ignacio María Suárez-Paul has participated in the acquisition of data and has approved the version presented.

Alejandra Virgós-Pedreira has participated in the acquisition of data and has approved the version presented.

Sonia Pértega-Díaz has participated in the analysis and interpretation of data, in the critical review of intellectual content, and has approved the version presented.

Ángeles Castro-Iglesias has participated in the conception and design of the study, in the critical review of the intellectual content, and has approved the version presented.

The authors declare no conflict of interest.